<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611596</url>
  </required_header>
  <id_info>
    <org_study_id>409189</org_study_id>
    <nct_id>NCT02611596</nct_id>
  </id_info>
  <brief_title>Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics</brief_title>
  <official_title>Does Ranolazine Decrease Biomarkers That Indicate Evidence of Myocardial Damage in Diabetics With Stable Ischemic Heart Disease? A Double-blinded, Randomized, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed National Military Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed National Military Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to compare subjects at high risk for silent myocardial
      ischemia in the placebo group to subjects at high risk for silent myocardial ischemia in the
      ranolazine group to determine if ranolazine can be used as a treatment to decrease silent
      myocardial ischemia (SMI). Subjects at high risk for silent myocardial ischemia are defined
      in this protocol as diabetics with stable ischemic heart disease. This study will look at the
      impact ranolazine treatment has on biomarkers that have been shown to be highly associated
      with increased risk of morbidity and mortality in relation to SMI. If the hypothesis is
      correct, further studies can be conducted to determine if treatment with ranolazine has
      impact on long-term outcomes such as hospitalizations, myocardial infarction, congestive
      heart failure or sudden cardiac death.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hs cTnT</measure>
    <time_frame>24 weeks</time_frame>
    <description>Does ranolazine decrease hs cTnT in subjects at high risk for silent myocardial ischemia?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NT-pro-BNP</measure>
    <time_frame>24 weeks</time_frame>
    <description>Does ranolazine decrease NT-pro-BNP in subjects at high risk for silent myocardial ischemia?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hsCRP</measure>
    <time_frame>24 weeks</time_frame>
    <description>Determine the degree of decrease of hs CRP in subjects in the ranolazine group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prevalence of hs cTnT &gt; 99th percentile</measure>
    <time_frame>24 weeks</time_frame>
    <description>Determine the prevalence of hs cTnT greater than the 99th percentile (0.014 ng/mL) in asymptomatic diabetic subjects with stable ischemic heart disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Silent Myocardial Ischemia</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take one 500mg tablet twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take one placebo tablet (identical to the 500mg Ranolazine tablet) twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>24 weeks of the assigned medication</description>
    <arm_group_label>Ranolazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects at risk for silent myocardial ischemia as defined by:

          -  Stable ischemic heart disease as defined by:

               -  Obstruction of at least one epicardial vessel of &gt; 50 percent by invasive or
                  non-invasive coronary angiography, or

               -  Evidence of ischemia or infarct on SPECT imaging, or

               -  History of myocardial infarction &gt; 3 months ago, or

               -  Stent placement (PCI) &gt; 3 months ago, or

               -  Coronary artery bypass grafting (CABG) &gt; 3 months ago AND

          -  Type 2 diabetics as defined by:

               -  HgbA1C ≥ 6.5 percent, or

               -  Fasting Blood Glucose &gt; 125 mg/dL on two or more blood draws, or

               -  Random Blood Glucose of ≥ 200 mg/dL on a single blood draw, or

               -  Previous diagnosis of type 2 diabetes listed in the subject's medical record AND

                  - On Optimal Medical Therapy as defined as being on ALL of the following at time
                  of enrollment:

               -  Beta Blocker

               -  Aspirin

               -  Statin AND

          -  Females &lt; 60 who have not been free of menstruation for 2 years (menopause diagnosed)
             or who do not have documented history of hysterectomy must be willing to use at least
             one form of birth control (including abstinence as an option) for the duration of the
             study. If condoms are the method chosen, they are strongly urged to use a second form
             of birth control in addition to condoms.

        AND

        Screening Criteria met:

        • hs cTnT &gt; 0.014 ng/mL

        Exclusion Criteria:

          -  Percutaneous intervention/stent placement in the past 3 months

          -  Coronary artery bypass grafting in the past 3 months

          -  Treatment with ranolazine in the past 12 months

          -  Significant lung disease, COPD or use of supplemental oxygen

          -  Cirrhosis

          -  Estimated Glomerular Filtration Rate (GFR) &lt; 30

          -  Subject taking strong CYP3A inhibitors (ketoconazole, itraconazole, clarithryomycin,
             nefazodone, nelfinavir, ritonavir, indinavir and saquinavir)

          -  Subject taking strong CYP3A inducers (rifampin, rifabutin, rifapentin, phenobarbital,
             phenytoin, carbamazepine, St. John's wort)

          -  Subjects taking P-gp Inhibitors (cyclosporine)

          -  Subject is taking concurrent simvastatin in &gt; 20 mg/day

          -  Subject is taking metformin &gt; 1700 mg/day

          -  NYHA Class 3 or 4 Heart Failure (severe)

          -  Canadian Cardiovascular Society Grade 4 Angina

          -  Unstable angina defined as a new angina occurring after minimal exercise or at rest OR
             a significant increase in angina severity (≥ 2 CCS grades) occurring with minimal
             exertion, with high clinical suspicion of acute coronary syndrome.

          -  Planned PCI or Cardiac Surgery

          -  Pregnant females or females trying to become pregnant

          -  Breast-feeding females

          -  Subjects younger than age 30 or older than age 85

          -  Lactose Intolerance (placebo has lactose monohydrate)

          -  Lactose/Milk allergy (placebo has lactose monohydrate)

          -  QTc &gt; 500 msec
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd C Villines, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WRNMMC</affiliation>
  </overall_official>
  <reference>
    <citation>Marzilli M, Merz CN, Boden WE, Bonow RO, Capozza PG, Chilian WM, DeMaria AN, Guarini G, Huqi A, Morrone D, Patel MR, Weintraub WS. Obstructive coronary atherosclerosis and ischemic heart disease: an elusive link! J Am Coll Cardiol. 2012 Sep 11;60(11):951-6. doi: 10.1016/j.jacc.2012.02.082. Review.</citation>
    <PMID>22954239</PMID>
  </reference>
  <reference>
    <citation>Cannon RO 3rd. Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms. J Am Coll Cardiol. 2009 Sep 1;54(10):877-85. doi: 10.1016/j.jacc.2009.03.080. Review.</citation>
    <PMID>19712795</PMID>
  </reference>
  <reference>
    <citation>Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation. 1990 Mar;81(3):748-56.</citation>
    <PMID>2306826</PMID>
  </reference>
  <reference>
    <citation>Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003 Jan 1;41(1):159-68.</citation>
    <PMID>12570960</PMID>
  </reference>
  <reference>
    <citation>Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011 Apr 5;123(13):1367-76. doi: 10.1161/CIRCULATIONAHA.110.005264. Epub 2011 Mar 21.</citation>
    <PMID>21422391</PMID>
  </reference>
  <reference>
    <citation>Hallén J, Johansen OE, Birkeland KI, Gullestad L, Aakhus S, Endresen K, Tjora S, Jaffe AS, Atar D. Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus. Cardiovasc Diabetol. 2010 Sep 15;9:52. doi: 10.1186/1475-2840-9-52.</citation>
    <PMID>20843304</PMID>
  </reference>
  <reference>
    <citation>Fornengo P, Bosio A, Epifani G, Pallisco O, Mancuso A, Pascale C. Prevalence of silent myocardial ischaemia in new-onset middle-aged Type 2 diabetic patients without other cardiovascular risk factors. Diabet Med. 2006 Jul;23(7):775-9.</citation>
    <PMID>16842483</PMID>
  </reference>
  <reference>
    <citation>Sprague RS, Ellsworth ML. Vascular disease in pre-diabetes: new insights derived from systems biology. Mo Med. 2010 Jul-Aug;107(4):265-9.</citation>
    <PMID>20806839</PMID>
  </reference>
  <reference>
    <citation>Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes. 2003 Dec;52(12):2867-73. Review.</citation>
    <PMID>14633845</PMID>
  </reference>
  <reference>
    <citation>Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008 Mar;31(3):464-9. Epub 2007 Nov 26.</citation>
    <PMID>18039804</PMID>
  </reference>
  <reference>
    <citation>Aranda JM Jr, Hill J. Cardiac transplant vasculopathy. Chest. 2000 Dec;118(6):1792-800. Review.</citation>
    <PMID>11115475</PMID>
  </reference>
  <reference>
    <citation>Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E; Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009 Dec 24;361(26):2538-47. doi: 10.1056/NEJMoa0805299. Epub 2009 Nov 25.</citation>
    <PMID>19940289</PMID>
  </reference>
  <reference>
    <citation>Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN; Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007 Sep 11;116(11):1242-9. Epub 2007 Aug 13.</citation>
    <PMID>17698733</PMID>
  </reference>
  <reference>
    <citation>Rubin J, Matsushita K, Ballantyne CM, Hoogeveen R, Coresh J, Selvin E. Chronic hyperglycemia and subclinical myocardial injury. J Am Coll Cardiol. 2012 Jan 31;59(5):484-9. doi: 10.1016/j.jacc.2011.10.875.</citation>
    <PMID>22281251</PMID>
  </reference>
  <reference>
    <citation>de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010 Dec 8;304(22):2503-12. doi: 10.1001/jama.2010.1768. Erratum in: JAMA. 2011 Mar 23;305(12):1200.</citation>
    <PMID>21139111</PMID>
  </reference>
  <reference>
    <citation>deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010 Dec 8;304(22):2494-502. doi: 10.1001/jama.2010.1708. Epub 2010 Nov 15.</citation>
    <PMID>21078811</PMID>
  </reference>
  <reference>
    <citation>Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol. 2012 Sep 11;60(11):960-8. doi: 10.1016/j.jacc.2012.04.049. Epub 2012 Aug 22.</citation>
    <PMID>22921971</PMID>
  </reference>
  <reference>
    <citation>Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol. 2010 Sep 14;56(12):934-42. doi: 10.1016/j.jacc.2010.04.042.</citation>
    <PMID>20828645</PMID>
  </reference>
  <reference>
    <citation>Deshmukh SH, Patel SR, Pinassi E, Mindrescu C, Hermance EV, Infantino MN, Coppola JT, Staniloae CS. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis. 2009 Aug;20(5):343-7. doi: 10.1097/MCA.0b013e32832a198b.</citation>
    <PMID>19444092</PMID>
  </reference>
  <reference>
    <citation>Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, Ben-Yehuda O, Katz A, Jones PG, Olmsted A, Belardinelli L, Chaitman BR. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013 May 21;61(20):2038-45. doi: 10.1016/j.jacc.2013.02.011. Epub 2013 Mar 10.</citation>
    <PMID>23500237</PMID>
  </reference>
  <reference>
    <citation>Gilead Sciences, Inc. Ranolazine Investigator's Brochure. Section 3.2.2 Placebo Tablets, 30 Mar 2012.</citation>
  </reference>
  <reference>
    <citation>FDA drug label for Ranolazine (Ranexa). Accessed via FDA website on 05 October 2012. Last revision Dec 2011. Reference ID: 3164047.</citation>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Walter Reed National Military Medical Center</investigator_affiliation>
    <investigator_full_name>Todd C. Villines</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

